Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Meribel Pharma Solna AB
AB
Active
Org 5568250095
Gårdsvägen 10 A, 169 70
Solna
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2010 · 15 years old
73 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Meribel Pharma Solna AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
149M
112M
75M
37M
0M
2020: 104M
104M
2020
2021: 100M (-4% vs 2020)
100M
-4%
2021
2022: 93M (-7% vs 2021)
93M
-7%
2022
2023: 120M (+29% vs 2022)
120M
+29%
2023
2024: 104M (-13% vs 2023)
104M
-13%
2024
EBITDA
SEK millions
24M
11M
-1M
-13M
-26M
2020: 6M
6M
2020
2021: -3M (-150% vs 2020)
-3M
-150%
2021
2022: -5M (-67% vs 2021)
-5M
-67%
2022
2023: 14M (+380% vs 2022)
14M
+380%
2023
2024: -16M (-214% vs 2023)
-16M
-214%
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
104 325
120 071
93 458
100 205
103 826
Staff expenses
—
—
—
—
—
EBITDA
−15 846
13 588
−4 546
−2 601
6 031
Depreciation & amort.
−3 412
−3 213
−3 377
−3 868
−4 105
EBIT
−19 258
10 375
−7 923
−6 469
1 926
Net financials
−341
−620
−136
38
−1 409
Profit before tax
−6 270
7 682
−8 059
−146
−63
Tax
−0
−1 511
1 511
−0
−0
Net profit
−6 270
6 171
−6 548
−146
−63
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
73 595
65 801
49 019
63 385
57 878
Equity
36 793
33 063
26 891
33 439
34 108
Long-term debt
0
0
0
0
33
Short-term debt
36 802
32 738
22 128
29 946
21 939
Total debt
36 802
32 738
22 128
29 946
21 972
Financial ratios
5-year trend
EBITDA margin
−15,2 %
This company
15,8 %
Market median
This company
Market median
196% below market
2020
2024
Equity ratio
50,0 %
This company
38,2 %
Market median
This company
Market median
31% above market
2020
2024
Return on equity
−17,0 %
This company
18,4 %
Market median
This company
Market median
192% below market
2020
2024
Net profit margin
−6,0 %
This company
8,1 %
Market median
This company
Market median
174% below market
2020
2024
Asset turnover
1,42×
This company
1,12×
Market median
This company
Market median
27% above market
2020
2024
Debt / equity
1,00×
This company
0,62×
Market median
This company
Market median
61% above market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Meribel Pharma Solna AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
